Drugs / CD19+22
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04626765 | Apr 2020 → Mar 2023 | childhood acute lymphoblastic leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19+22 | “CD19+22 CAR-T infusion for pediatric patients with CD19 positive and CD22 positive tumor cells” NCT04626765 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T Cell (CAR-T)” NCT04626765 ↗ |